Earth Science Tech, Inc. (ETST) Pursues Multi-National Development of CBD Formulations, Hemp-Based Superfood and Home Testing Kit
- In Canada and Brazil, ETST is lab testing three new cannabidiol formulations, developing two more CBD products and conducting studies on its Hygee device for women
- In the U.S., it is researching CBD’s impact on breast cancer and immune cells
- ETST is focused on the development of innovative products to reach its goal of becoming a world leader in the CBD space, with three new CBD formulas being developed under a provisory patent
Earth Science Tech, Inc. (OTC: ETST) is testing in Canada and Brazil a diverse mix of cannabidiol (CBD) formulations, including a superfood formula (http://nnw.fm/0gc1E). It is also conducting pre-launch lab studies of a medical device scheduled to be marketed internationally (http://nnw.fm/g4vqP).
ETST is a biotech company based in Doral, Florida, marketing and developing CBD products for the pharmaceutical and nutraceutical fields. The company manufactures, markets and distributes its own cannabinoid products, including capsules and oils. ETST has revamped its line of CBD products and will extend its line of raw dark chocolates with three new flavors in conjunction with joint venture partner Karmavore Superfoods. An anticipated launch is planned for the third quarter of 2018 (http://nnw.fm/HD4ga).
In Canada, the company is testing three new CBD IP formulations. They include a neuron protector and a breast protector. R&D is being conducted by the Centre de Developpement bioalimentaire du Quebec (CDBQ) or Quebec Agrifood Innovation Center (QAIC). An additional formulation will include a natural protective agent that will extend shelf life. A third product is a superfood that includes a mix of hemp oil and a highly potent antioxidant. In Quebec, the company is also clinically testing its Hygee MSN-2 medical device for detection of sexually transmitted infections (STIs) in women at the Clinique Santé Amitié.
ETST is developing two new products in Brazil through a joint venture with Bionatus Laboratrio Botnico of Brazil and its Canadian division, Bionatus Botanical Laboratories, Inc. The products are Propovit, enriched with ETST hemp oil, and a reformulation of Bionatus’ product featuring CBD.
In the U.S., it is conducting studies with the University of Central Oklahoma of high grade full spectrum CBD on breast cancer and immune cells.
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc., is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. ETST also recently formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- In Canada and Brazil, ETST is lab testing three new cannabidiol formulations, developing two more CBD products and conducting studies on its Hygee device for women
- In the U.S., it is researching CBD’s impact on breast cancer and immune cells
- ETST is focused on the development of innovative products to reach its goal of becoming a world leader in the CBD space, with three new CBD formulas being developed under a provisory patent
Earth Science Tech, Inc. (OTC: ETST) is testing in Canada and Brazil a diverse mix of cannabidiol (CBD) formulations, including a superfood formula (http://nnw.fm/0gc1E). It is also conducting pre-launch lab studies of a medical device scheduled to be marketed internationally (http://nnw.fm/g4vqP).
ETST is a biotech company based in Doral, Florida, marketing and developing CBD products for the pharmaceutical and nutraceutical fields. The company manufactures, markets and distributes its own cannabinoid products, including capsules and oils. ETST has revamped its line of CBD products and will extend its line of raw dark chocolates with three new flavors in conjunction with joint venture partner Karmavore Superfoods. An anticipated launch is planned for the third quarter of 2018 (http://nnw.fm/HD4ga).
In Canada, the company is testing three new CBD IP formulations. They include a neuron protector and a breast protector. R&D is being conducted by the Centre de Developpement bioalimentaire du Quebec (CDBQ) or Quebec Agrifood Innovation Center (QAIC). An additional formulation will include a natural protective agent that will extend shelf life. A third product is a superfood that includes a mix of hemp oil and a highly potent antioxidant. In Quebec, the company is also clinically testing its Hygee MSN-2 medical device for detection of sexually transmitted infections (STIs) in women at the Clinique Santé Amitié.
ETST is developing two new products in Brazil through a joint venture with Bionatus Laboratrio Botnico of Brazil and its Canadian division, Bionatus Botanical Laboratories, Inc. The products are Propovit, enriched with ETST hemp oil, and a reformulation of Bionatus’ product featuring CBD.
In the U.S., it is conducting studies with the University of Central Oklahoma of high grade full spectrum CBD on breast cancer and immune cells.
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc., is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. ETST also recently formed subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
